BioSpace News Archive

Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK.

Science 37 Holdings, Inc., the Agile Clinical Trial Operating System™, reported its financial results for the quarter ended June 30, 2022.

West Pharmaceutical Services, Inc. announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced that it has completed a financing with BDC Capital and iGan Ventures.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal platform delivery technology, reported financial results for the second quarter ended June 30, 2022, along with a corporate update.

Veru Inc. announced financial results for its fiscal 2022 third quarter ended June 30, 2022, and sabizabulin for COVID progress towards regulatory decisions in key territories.

ViewRay, Inc. announced that the National Cancer Center Hospital of Japan has upgraded its original Cobalt MRIdian® MRI-Guided Radiation Therapy System to the MRIdian Linac System and has treated its first patients.

Avivagen Inc. is pleased to announce that one of its most important customers in Asia has placed a new order for four tonnes of OxC-BetaTM Livestock to be used in Asia, in line with previous shipments fulfilled in 2021.

Cingulate Inc. announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, provided an update on its ophthalmology programs following feedback from the European Medicines Agency related to sepofarsen and will now focus exclusively on its Axiomer® RNA-editing technology platform.